Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse (Q36406313)

14 August 2017

Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse (English)

1 reference

Adaptive radiation therapy

14 August 2017

0 references

1 reference

3

Ted A Skolarus

1 reference

14 August 2017

4

Brent K Hollenbeck

1 reference

14 August 2017

Bruce L Jacobs

1

1 reference

14 August 2017

Yun Zhang

series ordinal

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 April 2012

1 reference

14 August 2017

1 reference

14 August 2017

31

1 reference

14 August 2017

4

1 reference

14 August 2017

750-759

1 reference

Cost implications of the rapid adoption of newer technologies for treating prostate cancer

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3500551

A Review of the Clinical Evidence for Intensity-modulated Radiotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3500551

Coverage with evidence development: ethical issues and policy implications

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3500551

Intensity-modulated radiation therapy: supportive data for prostate cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3500551

Recurrence in region of spared parotid gland after definitive intensity-modulated radiotherapy for head and neck cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3500551

Intensity-modulated radiation therapy use in the U.S., 2004.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3500551

Radiation-induced second cancers: the impact of 3D-CRT and IMRT

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3500551

Development of a comorbidity index using physician claims data

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3500551

Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3500551

Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3500551

Consequences of physicians' ownership of health care facilities--joint ventures in radiation therapy.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3500551

Reimbursement policy and androgen-deprivation therapy for prostate cancer

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3500551

Adding the patient perspective to comparative effectiveness research

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3500551

Integrated prostate cancer centers and over-utilization of IMRT: a close look at fee-for-service medicine in radiation oncology.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3500551

National health spending by medical condition, 1996-2005.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3500551

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3500551

Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3500551

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3500551

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3500551

Biotechnology and Medicare's new technology policy: lessons from three case studies

21 September 2018

1 reference

12 December 2020

Neighborhood of residence and incidence of coronary heart disease

1 reference

12 December 2020

The effects of payment method on clinical decision-making: physician responses to clinical scenarios

1 reference

12 December 2020

Intensity-modulated versus conventional pelvic radiotherapy for prostate cancer: analysis of acute toxicity

1 reference

12 December 2020

Medicare's coverage of colorectal cancer drugs: a case study in evidence development and policy

1 reference

12 December 2020

Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer

1 reference

12 December 2020

Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer

1 reference

12 December 2020

Incidence of Late Rectal and Urinary Toxicities After Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Localized Prostate Cancer

1 reference

12 December 2020

Quality of life and satisfaction with outcome among prostate-cancer survivors

1 reference

12 December 2020

Variations in quality of care for men with early-stage prostate cancer

1 reference

12 December 2020

Controlling the escalating use of advanced imaging: the role of radiology benefit management programs

1 reference

12 December 2020

10.1377/HLTHAFF.2011.1062

Identifiers

DOI

1 reference

14 August 2017

1 reference

14 August 2017

PubMed publication ID

22492892

1 reference